2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Myeloid, Acute
9
Leukemia
9
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Multiple Myeloma
4
Primary Immunodeficiency Diseases
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
AP 1903 reagent
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled